Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials
- Citation:
- Cancer Res vol 78 (4 Supplement) GS4-02
- Meeting Instance:
- SABCS 2017
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2920
- Pharmas:
- Grants:
- U10CA180821
- Corr. Author:
- Authors:
- Olivia Pagani Meredith M. Regan Gini F. Fleming Barbara A. Walley Marco Colleoni István Láng Henry L. Gomez Carlo Tondini Harold J. Brustein Matthew P. Goetz Eva M. Ciruelos Vered Stearns Hervé R. Bonefoi Silvana Martino Charles E. Geyer Jr. Graziella Pinotti Alan S. Coates Aron Goldhirsch Richard D. Gelber Prudence A. Francis
- Networks:
- LAPS-IL057, LAPS-MN026, LAPS-PA015, NY018, OH070, UPSTATE
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- IBCSG-24-02 (SOFT-TEXT), IBCSG-25-02 (TEXT)
- Phases:
- 3
- Keywords: